A 47-year-old woman with a rheumatologist-confirmed diagnosis of fibromyalgia presents for psychiatric evaluation reporting persistent depressive symptoms for the past four months. She describes widespread musculoskeletal pain rated 7 out of 10, fatigue despite sleeping 10 hours nightly, difficulty concentrating, low mood, and loss of interest in social activities. Her PHQ-9 is 16 and her Fibromyalgia Impact Questionnaire score is 62. She is currently taking acetaminophen and ibuprofen with minimal pain relief. She has no history of substance use disorder, and hepatic and renal function are normal. She has not previously tried any psychotropic medications. The PMHNP is planning an integrated treatment approach. Which pharmacological strategy best addresses both conditions?